Connor Clark & Lunn Investment Management Ltd. Takes Position in Sanofi (NASDAQ:SNY)

Connor Clark & Lunn Investment Management Ltd. bought a new position in Sanofi (NASDAQ:SNY - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 151,445 shares of the company's stock, valued at approximately $8,728,000.

Several other hedge funds and other institutional investors also recently modified their holdings of SNY. Stablepoint Partners LLC grew its stake in Sanofi by 0.8% during the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company's stock valued at $1,377,000 after acquiring an additional 189 shares in the last quarter. PDS Planning Inc boosted its holdings in Sanofi by 3.1% in the 3rd quarter. PDS Planning Inc now owns 6,643 shares of the company's stock valued at $383,000 after purchasing an additional 200 shares during the period. Eagle Ridge Investment Management grew its position in shares of Sanofi by 3.8% during the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company's stock valued at $321,000 after purchasing an additional 203 shares in the last quarter. Financial Advocates Investment Management increased its holdings in shares of Sanofi by 3.4% in the third quarter. Financial Advocates Investment Management now owns 6,327 shares of the company's stock worth $365,000 after purchasing an additional 206 shares during the period. Finally, Angeles Investment Advisors LLC raised its position in shares of Sanofi by 1.9% in the third quarter. Angeles Investment Advisors LLC now owns 11,323 shares of the company's stock worth $653,000 after buying an additional 210 shares in the last quarter. Institutional investors own 10.04% of the company's stock.

Analyst Ratings Changes

SNY has been the subject of a number of research reports. StockNews.com cut shares of Sanofi from a "strong-buy" rating to a "buy" rating in a research note on Thursday, November 7th. Citigroup raised Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Finally, Argus lifted their price target on Sanofi from $55.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, July 26th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $57.50.

Sanofi Trading Up 0.6 %

Shares of NASDAQ:SNY traded up $0.30 during midday trading on Friday, hitting $48.28. 2,010,526 shares of the stock traded hands, compared to its average volume of 2,044,243. The stock has a market capitalization of $122.53 billion, a PE ratio of 24.48, a P/E/G ratio of 1.22 and a beta of 0.61. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The business's 50 day moving average is $53.88 and its two-hundred day moving average is $52.16. Sanofi has a one year low of $45.22 and a one year high of $58.97.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. During the same period in the prior year, the company posted $2.55 earnings per share. The company's quarterly revenue was up 12.3% on a year-over-year basis. As a group, research analysts forecast that Sanofi will post 4.29 earnings per share for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.